Drug interactions
Erdafitinib + Metformin-repaglinide
Severity: Moderate
Erdafitinib and Metformin-repaglinide: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Erdafitinib is an OCT2 substrate, and metformin may compete for or inhibit renal tubular secretion, potentially raising erdafitinib levels. This may increase erdafitinib adverse effects, such as hyperphosphatemia and ocular or skin toxicity.
What this interaction means in plain words
Erdafitinib and Metformin-repaglinide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Erdafitinib belongs to Oncology; Metformin-repaglinide belongs to Endocrine.
Why it happens
Competition at renal OCT2 transporters reduces tubular secretion of erdafitinib.
What to do
Monitor for erdafitinib toxicity and consider dose reduction based on tolerability, or use an antidiabetic that is not an OCT2 substrate.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Erdafitinib and Metformin-repaglinide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Metformin-repaglinide
Other interactions of Erdafitinib
Frequently asked questions
Can I take Erdafitinib with Metformin-repaglinide?
MediHelp rates the interaction as moderate. Erdafitinib and Metformin-repaglinide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Erdafitinib is an OCT2 substrate, and metformin may compete for or inhibit renal tubular secretion, potentially raising erdafitinib levels. This may increase erdafitinib adverse effects, such as hyperphosphatemia and ocular or skin toxicity.
How serious is the interaction between Erdafitinib and Metformin-repaglinide?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for erdafitinib toxicity and consider dose reduction based on tolerability, or use an antidiabetic that is not an OCT2 substrate.
What other medicines interact with Metformin-repaglinide?
MediHelp also lists interactions of Metformin-repaglinide with, for example, Gemfibrozil, Apalutamide, Clarithromycin. The full list is on the Metformin-repaglinide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
